IN2012DN01864A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01864A IN2012DN01864A IN1864DEN2012A IN2012DN01864A IN 2012DN01864 A IN2012DN01864 A IN 2012DN01864A IN 1864DEN2012 A IN1864DEN2012 A IN 1864DEN2012A IN 2012DN01864 A IN2012DN01864 A IN 2012DN01864A
- Authority
- IN
- India
- Prior art keywords
- generating
- gas discharge
- constituted
- supported
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glanulating (AREA)
- Manufacture Of Metal Powder And Suspensions Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a floating granule comprising a solid core, on which an active ingredient is supported and also comprising a compound which is capable of generating a gas discharge which is constituted by an alkaline agent, characterised in that it does not comprise an acid agent which is capable of generating a gas discharge.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0955641A FR2949061B1 (en) | 2009-08-12 | 2009-08-12 | FLOATING MICROGRANULES |
PCT/FR2010/051691 WO2011018582A2 (en) | 2009-08-12 | 2010-08-11 | Floating microgranules |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN01864A true IN2012DN01864A (en) | 2015-08-21 |
Family
ID=42115979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1864DEN2012 IN2012DN01864A (en) | 2009-08-12 | 2010-08-11 |
Country Status (35)
Country | Link |
---|---|
US (1) | US8916202B2 (en) |
EP (1) | EP2464333B1 (en) |
JP (1) | JP6068142B2 (en) |
KR (2) | KR20120050477A (en) |
CN (1) | CN102548541B (en) |
AR (1) | AR077864A1 (en) |
AU (1) | AU2010283608B9 (en) |
BR (1) | BR112012003289B1 (en) |
CA (1) | CA2771053C (en) |
CL (1) | CL2012000376A1 (en) |
CY (1) | CY1118119T1 (en) |
DK (1) | DK2464333T3 (en) |
EA (1) | EA023532B1 (en) |
ES (1) | ES2588430T3 (en) |
FR (1) | FR2949061B1 (en) |
HK (1) | HK1172824A1 (en) |
HR (1) | HRP20161149T1 (en) |
HU (1) | HUE030027T2 (en) |
IL (1) | IL218072A (en) |
IN (1) | IN2012DN01864A (en) |
LT (1) | LT2464333T (en) |
MA (1) | MA33523B1 (en) |
MX (1) | MX2012001878A (en) |
NZ (1) | NZ598468A (en) |
PE (1) | PE20120805A1 (en) |
PL (1) | PL2464333T3 (en) |
PT (1) | PT2464333T (en) |
SG (1) | SG180305A1 (en) |
SI (1) | SI2464333T1 (en) |
SM (1) | SMT201600347B (en) |
TN (1) | TN2012000068A1 (en) |
TW (1) | TWI478731B (en) |
UA (1) | UA107361C2 (en) |
WO (1) | WO2011018582A2 (en) |
ZA (1) | ZA201201711B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
NZ581862A (en) | 2007-05-25 | 2012-06-29 | Tolmar Therapeutics Inc | Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient |
FR2938431B1 (en) | 2008-11-14 | 2013-12-20 | Debregeas Et Associes Pharma | NOVEL COMPOSITION BASED ON GAMMA-HYDROXYBUTYRIC ACID |
FR2949062B1 (en) | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | NEW PHARMACEUTICAL FORMULATIONS AGAINST MEASURING MEDICINES |
GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
US9321956B2 (en) | 2012-11-28 | 2016-04-26 | Halliburton Energy Services, Inc. | Methods for hindering the settling of particulates in a subterranean formation |
US9790774B2 (en) | 2014-01-02 | 2017-10-17 | Halliburton Energy Services, Inc. | Generating and maintaining conductivity of microfractures in tight formations by generating gas and heat |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
CA2989297A1 (en) | 2015-07-24 | 2017-02-02 | Halliburton Energy Services, Inc. | Microbubbles for heat and/or gas generation in subterranean formations |
CA2986545C (en) | 2015-07-24 | 2019-09-03 | Halliburton Energy Services, Inc. | Microbubbles for treatment chemical delivery in subterranean formations |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11666546B2 (en) | 2017-12-18 | 2023-06-06 | Tris Pharma, Inc | GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
CN112004520A (en) * | 2017-12-18 | 2020-11-27 | 特瑞斯制药公司 | Modified release drug powder compositions comprising a gastric retentive raft forming system with triggered pulsed drug release |
BR112021013766A2 (en) | 2019-03-01 | 2021-09-21 | Flamel Ireland Limited | GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH IMPROVED PHARMACOKINETICS IN THE FED STATE |
NL2024652B1 (en) * | 2020-01-10 | 2021-09-07 | Stabican B V | Process for preparing cannabinoid-containing particles |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5276418A (en) * | 1975-12-19 | 1977-06-27 | Microbial Chem Res Found | Method of preparing foamable micro-capsule preparations |
US4101650A (en) * | 1977-04-06 | 1978-07-18 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pepstatin floating minicapsules |
US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
JPS62195323A (en) * | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | Gastric resident particle |
IT1217783B (en) | 1988-06-03 | 1990-03-30 | Farmaceutico Ct S R L Lab | USE OF SALO DELL, BUTYRIC HYDROXIC ACID RANGE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS SUITABLE FOR USE IN THE ALCOHOLIC THERAPY AND RELATED COMPOSITIONS |
IT1248588B (en) | 1991-06-28 | 1995-01-19 | Gaetano Crepaldi | PHARMACEUTICAL COMPOSITIONS FOR THERAPY OF ABSTINENCE, "CRAVING", DEPENDENCE ON AMAZING SUBSTANCES, PSYCHOACTIVE SUBSTANCES, NICOTINE AND FOOD DISORDERS. |
IT1266565B1 (en) | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE ON THE BASIS OF ONE OR MORE PHARMACEUTICALLY ACCEPTABLE SALTS OF THE RANGE-HYDROXY-BUTYRIC ACID. |
US5824339A (en) | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
US6214386B1 (en) * | 1995-11-22 | 2001-04-10 | Recordati, S.A. | Prompt-release oral pharmaceutical compositions for extemporaneous suspensions |
US5846971A (en) | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
DE19630035A1 (en) | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol multiple unit formulations |
US6649186B1 (en) * | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
FR2762213B1 (en) * | 1997-04-18 | 1999-05-14 | Synthelabo | PHARMACEUTICAL COMPOSITION WITH GASTRIC RETENTION |
SE9702533D0 (en) * | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
JP3447042B2 (en) | 1997-07-23 | 2003-09-16 | フロイント産業株式会社 | Method for producing single substance spherical particles |
US20050244497A1 (en) * | 1997-11-05 | 2005-11-03 | Wockhardt Limited | Delayed delivery system for acid-sensitive drugs |
US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
FR2784583B1 (en) * | 1998-10-16 | 2002-01-25 | Synthelabo | PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE |
WO2000038672A2 (en) | 1998-12-23 | 2000-07-06 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
FR2797185B1 (en) * | 1999-08-06 | 2001-10-26 | Galenix Dev | FLOATING PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE AND A NON-ACTIVE PHASE |
FR2823668B1 (en) | 2001-04-20 | 2004-02-27 | Ethypharm Lab Prod Ethiques | ORODISPERSIBLE EFFERVESCENT TABLETS |
KR20040060917A (en) | 2001-08-06 | 2004-07-06 | 유로-셀티크 소시에떼 아노뉨 | Compositions and methods to prevent abuse of opioids |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US20030059397A1 (en) | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
FR2829932B1 (en) | 2001-09-21 | 2006-11-24 | Ellipse Pharmaceuticals | METHOD FOR MANUFACTURING ORALLY ADMINISTRATIVE PHARMACEUTICAL PRODUCT WITH REMOTE AGENTS AND PRODUCT OBTAINED |
CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
EP1536774A1 (en) | 2002-09-04 | 2005-06-08 | Ranbaxy Laboratories Limited | Taste masked dosage forms and processes for their preparation |
EP2422775A3 (en) | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
CN1964704A (en) | 2004-03-03 | 2007-05-16 | 特瓦制药工业有限公司 | Stable pharmaceutical composition comprising an acid labile drug |
TW200533391A (en) * | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
US8193211B2 (en) | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
WO2007002597A2 (en) | 2005-06-27 | 2007-01-04 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
ES2441766T3 (en) * | 2005-08-24 | 2014-02-06 | Endo Pharmaceuticals Inc. | Sustained-release nalbuphine formulations |
US20070092565A1 (en) * | 2005-10-25 | 2007-04-26 | Pharmascience Inc. | Gastric retention drug delivery system |
US9125833B2 (en) | 2005-11-02 | 2015-09-08 | Relmada Therapeutics, Inc. | Multimodal abuse resistant and extended release opioid formulations |
CA2633825A1 (en) * | 2005-12-20 | 2007-07-05 | Teva Pharmaceutical Industries Ltd. | Lansoprazole orally disintegrating tablets |
FR2898056B1 (en) | 2006-03-01 | 2012-01-20 | Ethypharm Sa | SQUEEZE-RESISTANT TABLETS TO PREVENT UNLAWFUL MISUSE |
JP2010534721A (en) * | 2007-07-27 | 2010-11-11 | ディポメド,インコーポレイティド | Pulse type gastric retentive preparation |
EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
FR2938431B1 (en) | 2008-11-14 | 2013-12-20 | Debregeas Et Associes Pharma | NOVEL COMPOSITION BASED ON GAMMA-HYDROXYBUTYRIC ACID |
FR2949062B1 (en) | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | NEW PHARMACEUTICAL FORMULATIONS AGAINST MEASURING MEDICINES |
-
2009
- 2009-08-12 FR FR0955641A patent/FR2949061B1/en not_active Expired - Fee Related
-
2010
- 2010-08-11 BR BR112012003289-5A patent/BR112012003289B1/en active IP Right Grant
- 2010-08-11 SM SM201600347T patent/SMT201600347B/en unknown
- 2010-08-11 IN IN1864DEN2012 patent/IN2012DN01864A/en unknown
- 2010-08-11 TW TW099126758A patent/TWI478731B/en active
- 2010-08-11 AU AU2010283608A patent/AU2010283608B9/en active Active
- 2010-08-11 WO PCT/FR2010/051691 patent/WO2011018582A2/en active Application Filing
- 2010-08-11 PL PL10761038.8T patent/PL2464333T3/en unknown
- 2010-08-11 MX MX2012001878A patent/MX2012001878A/en active IP Right Grant
- 2010-08-11 HU HUE10761038A patent/HUE030027T2/en unknown
- 2010-08-11 LT LTEP10761038.8T patent/LT2464333T/en unknown
- 2010-08-11 KR KR1020127006333A patent/KR20120050477A/en active Application Filing
- 2010-08-11 CN CN201080044056.7A patent/CN102548541B/en active Active
- 2010-08-11 NZ NZ598468A patent/NZ598468A/en unknown
- 2010-08-11 ES ES10761038.8T patent/ES2588430T3/en active Active
- 2010-08-11 SI SI201031271A patent/SI2464333T1/en unknown
- 2010-08-11 SG SG2012009965A patent/SG180305A1/en unknown
- 2010-08-11 CA CA2771053A patent/CA2771053C/en active Active
- 2010-08-11 DK DK10761038.8T patent/DK2464333T3/en active
- 2010-08-11 JP JP2012524262A patent/JP6068142B2/en active Active
- 2010-08-11 PT PT107610388T patent/PT2464333T/en unknown
- 2010-08-11 EA EA201200269A patent/EA023532B1/en not_active IP Right Cessation
- 2010-08-11 KR KR1020177030037A patent/KR20170119743A/en not_active Application Discontinuation
- 2010-08-11 US US13/390,217 patent/US8916202B2/en active Active
- 2010-08-11 EP EP10761038.8A patent/EP2464333B1/en active Active
- 2010-08-11 PE PE2012000216A patent/PE20120805A1/en not_active Application Discontinuation
- 2010-08-12 AR ARP100102964A patent/AR077864A1/en unknown
- 2010-11-08 UA UAA201202667A patent/UA107361C2/en unknown
-
2012
- 2012-02-13 TN TNP2012000068A patent/TN2012000068A1/en unknown
- 2012-02-13 MA MA34624A patent/MA33523B1/en unknown
- 2012-02-13 CL CL2012000376A patent/CL2012000376A1/en unknown
- 2012-02-13 IL IL218072A patent/IL218072A/en active IP Right Grant
- 2012-03-08 ZA ZA2012/01711A patent/ZA201201711B/en unknown
- 2012-12-31 HK HK12113624.3A patent/HK1172824A1/en unknown
-
2016
- 2016-09-06 HR HRP20161149TT patent/HRP20161149T1/en unknown
- 2016-09-26 CY CY20161100954T patent/CY1118119T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN01864A (en) | ||
MX362613B (en) | Effervescent gamma-hydroxybutyric acid granules. | |
IN2012DN01859A (en) | ||
IL216468A0 (en) | Compositions, methods & systems for respiratory respiratory delivery of two or more active agents | |
MY166613A (en) | Glycerol levulinate ketals and their use | |
MX356282B (en) | Compositions and methods comprising protease variants. | |
MX2012015187A (en) | Method for delivering an active agent. | |
WO2011002808A8 (en) | Hcv protease inhibitors and uses thereof | |
MX2013009175A (en) | Compositions comprising peroxy î±-ketocarboxylic acid and methods for producing and using the same. | |
GEP20135960B (en) | New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof | |
MY159251A (en) | Processes for the manufacture of a pharmaceutically active agent | |
UA100394C2 (en) | Lipoic acid pellet composition | |
MX2012009537A (en) | Solid forms comprising a cyclopropyl amide derivative. | |
TR200909785A1 (en) | Pharmaceutical compositions containing cefdinir as the active agent. | |
WO2010068920A3 (en) | Diaminoquinazoline inhibitors of dihydrofolate reductase | |
TW200940687A (en) | Antioxidant agent | |
WO2010111421A3 (en) | Isoform nell-1 peptide | |
WO2011031764A3 (en) | Compounds and related methods of use | |
EA200801449A1 (en) | GAP GRANULES | |
EA201100764A1 (en) | SOLID PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE STABILIZING AGENT | |
WO2010128755A3 (en) | Composition for preventing or treating hair loss containing threonate as an active ingredient | |
MY160482A (en) | Smoke grenade | |
WO2010129505A3 (en) | Napthylene inhibitors of cyclooxygenase | |
WO2008090850A1 (en) | Agent for enhancing the effect of anticancer agent | |
UA92872C2 (en) | combined antiaggregate and antioxidant drug |